SAMJIN PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20,300 KRW | +1.25% |
|
+2.11% | -6.02% |
| Jun. 03 | Samjin Pharmaceuticals Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares. | CI |
| Jun. 03 | Samjin Pharmaceuticals Co., Ltd. authorizes a Buyback Plan. | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Capitalization 1 | 327,511 | 344,067 |
| Enterprise Value (EV) 1 | 370,305 | 426,917 |
| P/E ratio | 11.4 x | 14.8 x |
| Yield | 3.04% | 3.12% |
| Capitalization / Revenue | 1.31 x | 1.26 x |
| EV / Revenue | 1.48 x | 1.56 x |
| EV / EBITDA | 8.97 x | 12.9 x |
| EV / FCF | - | -35,802,523 x |
| FCF Yield | - | -0% |
| Price to Book | 1.38 x | 1.23 x |
| Nbr of stocks (in thousands) | 12,453 | 13,414 |
| Reference price 2 | 26,300 | 25,650 |
| Announcement Date | 3/16/23 | 3/16/23 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Net sales 1 | 250,070 | 274,032 |
| EBITDA 1 | 41,272 | 33,000 |
| EBIT 1 | 33,911 | 23,184 |
| Operating Margin | 13.56% | 8.46% |
| Earnings before Tax (EBT) 1 | 34,911 | 25,226 |
| Net income 1 | 28,404 | 21,894 |
| Net margin | 11.36% | 7.99% |
| EPS 2 | 2,309 | 1,728 |
| Free Cash Flow | - | -11,924 |
| FCF margin | - | -4.35% |
| FCF Conversion (EBITDA) | - | - |
| FCF Conversion (Net income) | - | - |
| Dividend per Share 2 | 800.0 | 800.0 |
| Announcement Date | 3/16/23 | 3/16/23 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Net Debt 1 | 42,795 | 82,850 |
| Net Cash position 1 | - | - |
| Leverage (Debt/EBITDA) | 1.037 x | 2.511 x |
| Free Cash Flow | - | -11,924 |
| ROE (net income / shareholders' equity) | - | 8.59% |
| ROA (Net income/ Total Assets) | - | 3.92% |
| Assets 1 | - | 558,345 |
| Book Value Per Share 2 | 19,034 | 20,811 |
| Cash Flow per Share 2 | 645.0 | 177.0 |
| Capex 1 | 72,549 | 35,354 |
| Capex / Sales | 29.01% | 12.9% |
| Announcement Date | 3/16/23 | 3/16/23 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -6.02% | 190M | |
| +19.96% | 43.32B | |
| +20.38% | 22.81B | |
| +17.26% | 15.32B | |
| +23.93% | 14.91B | |
| +58.23% | 13.23B | |
| -0.05% | 6.79B | |
| -15.52% | 6.51B | |
| -8.87% | 5.73B | |
| +12.39% | 5.53B |
- Stock Market
- Equities
- A005500 Stock
- Financials Samjin Pharmaceuticals Co., Ltd.
